Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composite for treating B type diabetes

A technology of type 2 diabetes and composition, applied in the field of pharmaceutical composition for treating type 2 diabetes

Inactive Publication Date: 2010-04-28
SHANDONG UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical applications, there are frequent reports in the literature of cases of hypersensitivity to animal insulin, recombinant human insulin, and even insulin analogs, requiring additional anti-allergic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composite for treating B type diabetes
  • Medicine composite for treating B type diabetes
  • Medicine composite for treating B type diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Porcine insulin + cromolyn sodium oral microsphere preparation

[0020] Sodium cromoglycate 800mg is dissolved in 20ml of water for injection; Porcine insulin 6mg is dissolved in 30ml of 0.01mol / L hydrochloric acid; Sodium deoxycholate 4.0mg is mixed with disodium edetate 12.0mg; Acrylic resin II 600mg is dissolved in 20ml Soak in 90% ethanol overnight to dissolve. Mix the above four mixtures evenly, mix with 700ml liquid paraffin for 30min under stirring at 600r / min, slowly add 150ml of 0.5% gelatin solution and stir for 20min until the microspheres are solidified. The precipitate was collected by centrifugation, washed three times with an appropriate amount of petroleum ether, and dried under reduced pressure at 50°C for 12 hours to obtain porcine insulin cromolyn sodium enteric-coated microspheres.

[0021] The particle size distribution analysis is carried out with a scanning electron microscope image analyzer, and the average particle size is 4.96 μm, and the numb...

Embodiment 2

[0023] Recombinant human insulin + cromolyn sodium oral microsphere preparation

[0024] Sodium cromoglycate 600mg was dissolved in 10ml of water for injection; recombinant human insulin 3mg was dissolved in 20ml of 0.01mol / L hydrochloric acid; sodium deoxycholate 2.0mg was mixed with disodium edetate 6.0mg; acrylic resin II 300mg was dissolved in Soak in 20ml 90% ethanol overnight to dissolve. Mix the above four mixtures evenly, mix with 500ml liquid paraffin for 30min under stirring at 600r / min, slowly add 100ml of 0.5% gelatin solution and stir for 20min until the microspheres are solidified. The precipitate was collected by centrifugation, washed three times with an appropriate amount of petroleum ether, and dried under reduced pressure at 50°C for 12 hours to obtain recombinant human insulin cromolyn sodium enteric-coated microspheres.

[0025] The particle size distribution analysis is carried out with a scanning electron microscope image analyzer, and the average parti...

Embodiment 3

[0027] Porcine insulin + ketotifen fumarate oral microsphere preparation

[0028] 15 mg of ketotifen fumarate and 10 mg of porcine insulin were mixed evenly, and 4.0 g of sodium deoxycholate was added and mixed evenly; 300 g of chitosan (molecular weight was 3.84~6.12×10 5 ) was dissolved in 400ml of dichloromethane, then the above solid mixture was added into the solution, and ultrasonically emulsified for 30min. Add the emulsion to 850ml of 1.5% polyvinyl alcohol solution (W / V), stir at room temperature at 600r / min for 12h, and form microspheres. The particle size distribution analysis is carried out with a scanning electron microscope image analyzer, the average particle size is 5.39 μm, the number of microspheres in the range of 4-8 μm exceeds 62%, and the encapsulation efficiency is 75%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a medicine composite for treating B type diabetes, which comprises a trypsin class medicine and an antiallergic medicine, wherein the weight ratio of the trypsin class medicine to the antiallergic medicine is 1:(1.5-1700). When being taken, the medicine composite can be prepared into various medicament forms, such as an oral microsphere preparation or injection and the like. The trypsin class medicine is any one of recombinant human trypsin, pig trypsin and dulcin trypsin. The antiallergic medicine is sodium cromoglyate or / and ketotifen fumarate. Animal experiments prove that the trypsin class medicine and the antiallergic medicine are combined according to a certain proportion, which not only can prevent the generation of trypsin allergy but also can enhance the blood sugar control action of trypsin and lighten the obesity degree. The action mechanism of the medicine composite is to regulate the excessive mast cells of the fat tissues of patients with obesity and diabetes by two antiallergic medicines of the sodium cromoglyate and the ketotifen fumarate, thereby exerting a synergistic action with the trypsin and preventing and relieving the anaphylactic reaction of the trypsin.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating type 2 diabetes. Background technique [0002] Type 2 diabetes, also known as adult-onset diabetes, mostly occurs after the age of 35-40, accounting for more than 90% of diabetic patients. With the improvement of living standards, the incidence of type 2 diabetes in children also has a rising trend. Its prevalence has increased rapidly in the past 50 years, and the number of patients in my country has approached 20 million, which has brought a heavy economic burden to the society and individuals, and seriously affected the quality of life of patients and even endangered their lives. [0003] With the continuous development of medical research, diabetes treatment drugs are also increasing day by day. The current clinically used or under development diabetes chemotherapeutic drugs mainly include: insulin and its analogues (such as animal insulin, genetically engineered human insulin, insu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K38/28A61P3/10A61K31/4535A61K31/352
Inventor 厉保秋
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com